ライフサイエンスコーパス: effusion

1 nodules, lymph node enlargement, and pleural effusion).

2 caused by the volume effect of the choroidal effusion.

3 required intensive care and 26% had pleural effusion.

4 e development of recurrent otitis media with effusion.

5 demonstrated a moderate to large pericardial effusion.

6 thyroiditis and pneumonia with left pleural effusion.

7 stitial syndrome, consolidation, and pleural effusion.

8 MPP children or in MPP children with pleural effusion.

9 as well as ascites and a left-sided pleural effusion.

10 aracters, such as refractoriness and pleural effusion.

11 and interatrial septum and mild pericardial effusion.

12 ion after excluding one patient with pleural effusion.

13 ory device position and excluded pericardial effusion.

14 lobe mass along with a moderate-size pleural effusion.

15 d pulmonary edema with a small right pleural effusion.

16 y diagnose tuberculous and malignant pleural effusion.

17 vidence for late pericardial inflammation or effusion.

18 wed an enlarged heart with bilateral pleural effusion.

19 efinitive treatment of recurrent symptomatic effusion.

20 rial mass and moderate to severe pericardial effusion.

21 lectrocardiographic changes, and pericardial effusion.

22 btained and indicated increasing pericardial effusion.

23 al space as seen in other forms of choroidal effusion.

24 and one patient with chronic chylous pleural effusion.

25 r bronchogram, nodular opacities and pleural effusion.

26 r pneumonia on chest radiograph, and pleural effusion.

27 es and, at times, accompanied by pericardial effusion.

28 enchymal calcification and left-sided plural effusion.

29 al thickening coupled with a massive pleural effusion.

30 ocytopenia, grade 4 neutropenia, and pleural effusion.

31 f chylous and nonchylous ascites and pleural effusions.

32 ed with hemothoraces rather than pericardial effusions.

33 sociated pneumonia, atelectasis, and pleural effusions.

34 pleural effusions from transudative pleural effusions.

35 ptide-encoding gene in chinchilla middle ear effusions.

36 duces complication rates, particularly uveal effusions.

37 edema and fibrosis and frequent pericardial effusions.

38 effusions, chylothoraces and/or pericardial effusions.

39 nts limits or delays clearance of middle ear effusions.

40 Cs are elevated in MPEs compared with benign effusions.

41 presented with worsening dyspnea and pleural effusions.

42 erventions in patients with thoracic chylous effusions.

43 tracer of air contamination in volcanic gas effusions.

44 ight ventricular dysfunction and pericardial effusions.

45 or differentiation of chylous and nonchylous effusions.

46 de-separate reading scores for pneumonia and effusion (0 = absent, 1 = possible, and 2 = highly suspe

47 cartilage [3.0% vs 0.3%, P = .006] and joint effusion [0.3% vs 2.7%, P = .005]).

48 spontaneously resolving) included choroidal effusion (1), vitreous hemorrhage (3), Descemet detachme

49 occurred in 5 patients (0.4%): 2 pericardial effusions (1 intraoperative, 1 after 30 days, both drain

50 2% vs 40.5%, P < 0.001), symptomatic pleural effusion (11.6% vs 26.4%, P = 0.003), pleural effusion r

51 intrathoracic lymphadenopathy (16%), pleural effusion (12%), reticular infiltration (4%), and pericar

52 rvival compared with those with nonmalignant effusions (16.2% vs. 49.0%, respectively; log-rank test

53 omes (ACS) (1C), the presence of pericardial effusion (1C), cardiac tamponade (1B), valvular dysfunct

54 , bone marrow edema (39 of 40 vs 87 of 100), effusion (20 of 40 vs 26 of 100), abductor tendon lesion

55 reticular infiltration (4%), and pericardial effusion (4%).

56 , corneal decompensation (6%), and choroidal effusion (4%).

57 ltoid bursa/long head of bicep tendon sheath effusion (44.4%), and long head of bicep tendon sheath e

58 of 200, respectively; P < .001) and pleural effusions (47 [23.5%] of 200 vs 16 [8%] of 200, respecti

59 esent in 9); edema (9); respiratory (6); and effusions (5).

60 and/or abdominal collections (9.3%), pleural effusion (8.3%), postoperative bleeding (5.6%), and othe

61 23%), mass-like consolidation (17%), pleural effusion (8.6%), and honey combing (5.7%).

62 the rare disseminated tumor cells in pleural effusions across a panel of 32 lung adenocarcinoma patie

63 atic cardiac events (symptomatic pericardial effusion, acute coronary syndrome, pericarditis, signifi

64 tomy, there were no instances of pericardial effusion after extraction.

65 Pleural effusion agreement also differed between pulmonary ultra

66 tive diagnosis using a serology, pericardial effusion analysis or biopsy.

67 ndinosis, subacromial-subdeltoid bursitis or effusion and adhesive capsulitis.

68 ures was strong (eg, alpha = .78 for pleural effusion and ascites) but was lower for others (eg, alph

69 use of ultrasonography for ruling-in pleural effusion and assisting its drainage, ascites drainage, r

70 r cells isolated from the metastatic pleural effusion and atypical ductal hyperplasia mammary tumor s

71 cally as interstitial pneumonia with pleural effusion and clinically as hypoxemic respiratory insuffi

72 cute severe pericarditis delayed pericardial effusion and gastrointestinal adverse effects were simil

73 e to pulmonary oedema and one due to pleural effusion and pneumonitis).

74 pigastric pain was found to have pericardial effusion and pneumopericardium on computed imaging.

75 Suprapatellar effusion and reduced lateral femoral cartilage thickness

76 gl1-depleted embryos ameliorated pericardial effusion and restored blood flow velocity.

77 opment of myopia, lens thickening, choroidal effusion and retinal striae at the macula with the incre

78 ouse models of malignant lung cancer pleural effusion and spontaneous colon cancer metastasis.

79 wich ELISA on 93 patients with parapneumonic effusions and 47 control subjects (benign and malignant

80 ng more invasive management of parapneumonic effusions and added value to conventional biomarkers.

81 o patients, including one with large pleural effusions and another with ventricular tachycardia, were

82 itoneal spread, presence and size of pleural effusions and ascites, lymphadenopathy, and distant meta

83 air/tissue interface) and real images (i.e., effusions and consolidations), both providing significan

84 improve the drainage of complicated pleural effusions and empyemas and it is the most effective drug

85 sions, and the presence of bilateral pleural effusions and multi-lobar atelectasis/consolidation, whi

86 Pericardial effusions and myocardial fibrosis were 3 and 4x more com

87 tly post antibiotic treatment in the pleural effusions and pleural macrophages up-regulated markers c

88 dothelial necrosis surrounded by hemorrhagic effusions and pulmonary edema.

89 tumor, pleural metastases, malignant pleural effusion, and ascites obtained during disease progressio

90 thickening of the gallbladder wall, pleural effusion, and ascites.

91 perennial rhinosinusitis, otitis media with effusion, and bronchiectasis.

92 were shock, cardiac arrhythmias, pericardial effusion, and coronary artery dilatation.

93 est a strong impact of PCV13 on CAP, pleural effusion, and documented pneumococcal pneumonia, particu

94 rtate aminotransferase, syncope, pericardial effusion, and hyperkalaemia, and grade 4 increased alani

95 l femoral cartilage thickness, suprapatellar effusion, and irregular cartilage-bone margin, were simi

96 Reported events included seizure, pleural effusion, and lymphocytopenia.

97 endicitis, spontaneous abortion, pericardial effusion, and seizure; none of the events occurred withi

98 toms are bilateral lower limb edema, serosal effusions, and vitamin D malabsorption resulting in oste

99 rtic or mitral valve disease, or pericardial effusion; and used transthoracic echocardiography as the

100 creased gall bladder wall thickness, pleural effusion, ascites, hepatomegaly, and splenomegaly are hi

101 ar Collapse, Targeted Physiotherapy, Pleural Effusion assessment, and PEEP optimisation.

102 MGAS5005 induced vascular effusion at infection sites at early hours after GAS ino

103 precipitates sourced from hydrothermal brine effusion at many individual sites, coalescing in several

104 trial involving patients with large pleural effusions at two academic medical centres in, Nashville,

105 y infection, aspiration pneumonitis, pleural effusion, atelectasis, cardiopulmonary edema, and pneumo

106 ing emphysema, cardiomegaly, hernias, edema, effusions, atelectasis, masses, and nodules.

107 1 patient developed pericardial and pleural effusion attributed to pericardial instrumentation.

108 There were no pericardial effusions, but serious procedure/device-related events o

109 bular septal thickening, possibly with small effusions, but without clinical evidence of volume overl

110 th external drainage for nanophthalmic uveal effusion can provide immediate and stable gain in vision

111 ding bleb leak, hypotony, hyphema, choroidal effusion, choroidal hemorrhage, blebitis, and endophthal

112 l and/or pulmonary lymphangiectasia, pleural effusions, chylothoraces and/or pericardial effusions.

113 Chylous pleural effusion (chylothorax) frequently accompanies lymphatic

114 Moreover, chronic OM with effusion (COME) is the leading cause of conductive heari

115 Chronic otitis media with effusion (COME) is the most common cause of hearing loss

116 Among patients with malignant pleural effusion, daily drainage of pleural fluid via an indwell

117 MCs were required for effusion development, as MPEs did not form in mice lacki

118 ted congestive heart failure and pericardial effusion diagnosed on echocardiography.

119 gher morbidity of tachypnea/dyspnea, pleural effusion, diarrhea, hepatosplenomegaly, consciousness al

120 Middle ear effusion disappeared 2.0 weeks (13.7 days) earlier (P =

121 NK cells isolated from inflammatory pleural effusions display a potent regulatory activity.

122 r endoleak correction, and 2 for pericardial effusion drainage.

123 meter malfunction (n=2), inability to access effusion due to pleural tumour burden (n=1), and inabili

124 eeks plus tremelimumab 1 mg/kg), pericardial effusion (durvalumab 20 mg/kg every 4 weeks plus tremeli

125 With no cure for malignant pleural effusion, efforts are focused on symptomatic management.

126 Here we report that brine effusion emplaced the faculae in a brine-limited, impact

127 ns of local complications (eg, parapneumonic effusion, empyema, necrotising pneumonia, and lung absce

128 gible patients were adults with free-flowing effusions estimated to be at least 0.5 L who could remai

129 Materials and Methods Patients with chylous effusions evaluated from January 2014 and December 2017

130 [5%]), cholangitis (five [3%]), and pleural effusion (five [3%]).

131 agnosis requires cytologic evaluation of the effusion fluid surrounding the affected implant.

132 trifugation and filtration of fresh, unfixed effusion fluid to produce air-dried smears that are stai

133 MPE formation and suggest that MC-dependent effusion formation is therapeutically addressable.

134 o detected CXCL12-gamma in malignant pleural effusions from patients with breast cancer.

135 an help in differentiating exudative pleural effusions from transudative pleural effusions.

136 severe leakage, fluid accumulation, pleural effusion, gall-bladder wall thickening and rapid haemato

137 al pulmonary infiltrates group or in pleural effusion group.

138 Lung cancer patients with proven malignant effusions had a significantly shorter median 1-year surv

139 Rationale: Parapneumonic effusions have a wide clinical spectrum.

140 RATIONALE: Patients with malignant pleural effusions have significant dyspnea and shortened life ex

141 4; P<0.001), and the presence of pericardial effusion (HR, 1.38; 95% confidence interval, 1.023-1.862

142 r and dysmorphic cardiomyocytes, pericardial effusion, impaired blood flow and aberrant valvulogenesi

143 9.5%) patients including symptomatic pleural effusion in 366 (30.1%) patients, respiratory insufficie

144 ng using the Management of Otitis Media with Effusion in Children with Cleft Palate study scoring sys

145 defined as abnormal central lymphatic flow, effusions in more than 1 compartment, and dermal backflo

146 cifically disrupts the BTB and enhances drug effusion into brain tumors.

147 TB, but not the BBB, thereby increasing drug effusion into established tumors and enhancing the chemo

148 eniscus, cartilage, bone marrow edema, joint effusion, ligaments, tendons) were examined for an assoc

149 Most cases are of effusion-limited, indolent disease, with an excellent pr

150 ied by hypotension and cyanosis, pericardial effusion, low voltage on the electrocardiogram, marked e

151 1), plasmablastic lymphoma (n = 15), primary effusion lymphoma (n = 7), unclassifiable B-cell NHL (n

152 of reactivated lytic replication in primary effusion lymphoma (PEL) and endothelial cells and sustai

153 nocompromised individuals, including primary effusion lymphoma (PEL) and Kaposi's sarcoma (KS).

154 orders of these cells manifesting as primary effusion lymphoma (PEL) and multicentric Castleman disea

155 ciated with two B cell malignancies, primary effusion lymphoma (PEL) and the plasmablastic variant of

156 Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL) are two well-known inflammation

157 ay.IMPORTANCE One hundred percent of primary effusion lymphoma (PEL) cases are associated with Kaposi

158 ly impacting HHV-8 latently infected primary effusion lymphoma (PEL) cell viability and reactivated v

159 o the viability of latently infected primary effusion lymphoma (PEL) cells and to HHV-8 productive re

160 ll ~100 copies of the KSHV genome in primary effusion lymphoma (PEL) cells by coexpressing two guide

161 iASPP to KSHV-infected-cell growth, primary effusion lymphoma (PEL) cells were treated with an iASPP

162 are also expressed during latency in primary effusion lymphoma (PEL) cells, and vIRF-1 and vIRF-3 hav

163 In primary effusion lymphoma (PEL) cells, vIL-6 is expressed latent

164 nesis and the survival and growth of primary effusion lymphoma (PEL) cells.

165 n, and proliferation of BCR-negative primary effusion lymphoma (PEL) cells.

166 is necessary but not sufficient for primary effusion lymphoma (PEL) development.

167 Primary effusion lymphoma (PEL) has a very poor prognosis.

168 Primary effusion lymphoma (PEL) is a highly aggressive B-cell ma

169 Primary effusion lymphoma (PEL) is a largely incurable malignanc

170 Primary effusion lymphoma (PEL) is a lymphogenic disorder associ

171 Primary effusion lymphoma (PEL) is a rare B-cell neoplasm in whi

172 Primary effusion lymphoma (PEL) is a subtype of non-Hodgkin lymp

173 Primary effusion lymphoma (PEL) is an aggressive HIV-associated

174 Primary effusion lymphoma (PEL) is an aggressive malignancy with

175 Primary effusion lymphoma (PEL) is an aggressive type of non-Hod

176 or the survival and proliferation of primary effusion lymphoma (PEL), an aggressive malignancy associ

177 KSHV is linked to primary effusion lymphoma (PEL), and 90% of PELs also contain EB

178 is the cause of Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and a form of Castleman disease

179 ative agent for Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and a subset of multicentric Ca

180 ative agent for Kaposi sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman dise

181 o HHV-8-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castleman's di

182 sociated with Kaposi's sarcoma (KS), primary effusion lymphoma (PEL), and multicentric Castleman's di

183 o virus-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castleman's di

184 n HHV-8-associated Kaposi's sarcoma, primary effusion lymphoma (PEL), and multicentric Castleman's di

185 d and important for cell survival in primary effusion lymphoma (PEL), which is a viral lymphoma infec

186 icentric Castleman disease (MCD) and primary effusion lymphoma (PEL).

187 including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

188 including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

189 with several malignancies, including primary effusion lymphoma (PEL).

190 including Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

191 ogical agent of Kaposi's sarcoma and primary effusion lymphoma (PEL).

192 uppression of NF-kappaB signaling in primary effusion lymphoma (PEL).

193 c agent of Kaposi's sarcoma (KS) and primary effusion lymphoma (PEL).

194 , multicentric Castleman disease, or primary effusion lymphoma and 8 HIV-uninfected men receiving HIV

195 svirus that has been associated with primary effusion lymphoma and multicentric Castleman's disease,

196 iated herpesvirus (KSHV)-transformed primary effusion lymphoma cell lines contain ~70 to 150 copies o

197 n ChIP/deep sequencing from infected primary effusion lymphoma cells revealed that RBP-Jkappa binds n

198 entric Castleman disease, and 1 with primary effusion lymphoma) and 1 asymptomatic PrEP user had a ne

199 l as a rare form of B cell lymphoma (primary effusion lymphoma) primarily observed in HIV-infected in

200 lymphomas, such as Hodgkin lymphoma, primary effusion lymphoma, and a diffuse large B-cell lymphoma s

201 s: multicentric Castleman's disease, primary effusion lymphoma, and Kaposi's sarcoma.

202 gic agent underlying Kaposi sarcoma, primary effusion lymphoma, and multicentric Castleman's disease.

203 us (KSHV) is tightly linked with KS, primary effusion lymphoma, and multicentric Castleman's disease.

204 Primary effusion lymphomas (PEL) are associated with human herpe

205 Primary effusion lymphomas (PELs) are causally associated with K

206 merous human malignancies, including primary effusion lymphomas (PELs).

207 romatic compounds are measured using Knudsen Effusion Mass Spectrometry (KEMS) over a range of temper

208 atrial fibrillation (AF), and postoperative effusions may be responsible for increased morbidity and

209 nd 47 control subjects (benign and malignant effusions).Measurements and Main Results: Pleural suPAR

210 loculated versus nonloculated parapneumonic effusions (median, 132 ng/ml vs. 22 ng/ml; P < 0.001).

211 n (microbiota) present in matched middle ear effusion (MEE) samples, external ear canal (EEC) lavages

212 and lactate dehydrogenase) in parapneumonic effusions.Methods: Patients presenting with pleural effu

213 MPE formation in a human cancer cell-induced effusion model.

214 Malignant pleural effusion (MPE) confers dismal prognosis and has limited

215 Malignant pleural effusion (MPE) is challenging to manage.

216 Malignant pleural effusion (MPE) is the lethal consequence of various huma

217 al effusion (TPE, n = 50), malignant pleural effusion (MPE, n = 41), other cases including pneumonia

218 ed MCs in human and murine malignant pleural effusions (MPEs) and evaluated the fate and function of

219 and soft tissue oedema, presence of synovial effusion, muscular atrophy in the affected extremity, os

220 (n = 9), pupillary block (n = 1), choroidal effusion (n = 2), CME (n = 4), and redislocation (n = 1)

221 =1 [2%]), skin infection (n=1 [2%]), pleural effusion (n=1 [2%]), pericardial infusion (n=1 [2%]), up

222 3 [5%]), pneumonitis (n=3 [5%]), pericardial effusion (n=2 [3%]), and upper respiratory infection (n=

223 nts at a median of 26 months to first event (effusion [n = 7], myocardial infarction [n = 5], unstabl

224 included age, ejection fraction, pericardial effusion, N-terminal pro-B-type natriuretic peptide, and

225 For treatment of malignant pleural effusion, nonsteroidal anti-inflammatory drugs (NSAIDs)

226 Background Diagnosis of chylous effusions normally requires invasive paracentesis.

227 changed the management of malignant pleural effusion, not solely by offering an alternative manageme

228 osive eruptions with accompanying rapid lava effusion occurred between 25 and 29 November.

229 A pericardial effusion occurred in 1 patient: pericardiocentesis was p

230 terval, 1.4-6.2; P<0.001), and a pericardial effusion (odds ratio, 2.5; 95% confidence interval, 1.1-

231 cellular cancer structures cells from plural effusions of cancer patients.

232 Otitis media with effusion (OME) is a common inflammatory disease that pri

233 Chronic Otitis media with effusion (OME) often leads to conductive hearing loss an

234 values in the area of the greatest amount of effusion on each slice of the three slices used.

235 l lung involvement, crazy paving and pleural effusion on initial CT chest have potential prognostic v

236 ndred and twenty eight patients with pleural effusions on thoracic CT who underwent thoracentesisis w

237 44.4%), and long head of bicep tendon sheath effusion only (40%).

238 Patients with NSCLC (stage IIIB with pleural effusion or stage IV according to American Joint Committ

239 be complicated by either a large pericardial effusion or tamponade, and carry a significant risk of r

240 C [>100.4 degrees F], subacute course, large effusion or tamponade, and failure of nonsteroidal anti-

241 , myocardial infarction, stroke, pericardial effusion or tamponade, percutaneous coronary interventio

242 l maceration (OR, 1.84; 95% CI: 1.13, 2.99), effusion (OR, 4.75; 95% CI: 2.55, 8.85), or synovitis (O

243 est odds of readmission, followed by pleural effusion [OR 7.52 (95% CI, 6.01-9.41)], pneumothorax [OR

244 , who also exhibit polycythemia, pericardial effusion, or goiter should be evaluated for cobalt expos

245 eripheric soft tissue and bone marrow, joint effusion, or synovitis are more severe than the lesion i

246 my group, eyes developed postoperative uveal effusions (P = .04).

247 Pericardial effusion (PE) is common in cancer patients, but the opti

248 ents had bleeding complications (pericardial effusion, pericardial hematoma, hemoperitoneum, and peri

249 ME), without any signs of infection and with effusion persisting in the ME for more than 3 months.

250 (33.3%) major complications, such as pleural effusion, pneumothoraces or perihepatic hemorrhages were

251 ary congestion, respiratory failure, pleural effusion, pneumothorax, or unplanned requirement for pos

252 n of post-Fontan hospitalization and pleural effusion, postoperative plastic bronchitis, need for tra

253 he c-KIT inhibitor imatinib mesylate limited effusion precipitation by mouse and human adenocarcinoma

254 l damage, meniscal extrusion, synovitis, and effusion prior to reported knee replacement.

255 l performance index, presence of pericardial effusion, pulmonary vascular resistance, cardiac index,

256 irmed or suspected mesothelioma with pleural effusion, recruited from 12 hospitals in the UK.

257 Procedure-related complications, effusion recurrence rate, and overall survival were anal

258 ffusion (11.6% vs 26.4%, P = 0.003), pleural effusion requiring drainage (1.7% vs 9.9%, P = 0.006), a

259 e most common complications were pericardial effusion requiring intervention (1.39%) and major bleedi

260 Evaluation of human effusions revealed that MCs are elevated in MPEs compare

261 igns (ie, halo sign, hypodense sign, pleural effusion, reversed halo sign) is unknown.

262 Effusion's model makes it practical to integrate rare ex

263 We demonstrate Effusion's performance using a critical evaluation metho

264 mediastinal lymphadenopathy and pericardial effusion, showed no statistically significant difference

265 dyspnoea (six [2%] vs one [1%]), and pleural effusion (six [2%] vs none).

266 were thrombocytopenia (eight [11%]), pleural effusion (six [8%]), and increased lipase (five [7%]).

267 nce of fetal ascites, pleural or pericardial effusions, skin edema, cystic hygroma, increased nuchal

268 ocused on the processing of the seroma fluid/effusion surrounding the implant, the handling of capsul

269 t an unusual case of non-nanophthalmic uveal effusion syndrome (UES) with histologically normal scler

270 Uveal effusion syndrome is a rare entity of idiopathic exudati

271 me, we report 2 cases of nanophthalmic uveal effusion syndrome managed with our technique.

272 al suPAR levels were significantly higher in effusions that were loculated versus nonloculated parapn

273 Regarding the detection of pleural effusions, there was no significant performance differen

274 Among patients with malignant pleural effusion, thoracoscopic talc poudrage, compared with tal

275 hylous versus nonchylous ascites and pleural effusions through use of multipoint Dixon fat quantifica

276 ssion from a non-infected, pneumonia-related effusion to a confirmed pleural infection have been well

277 lled 91 cases, including tuberculous pleural effusion (TPE, n = 50), malignant pleural effusion (MPE,

278 complications included a single pericardial effusion treated with percutaneous drainage and a left v

279 ia (four [3%]), and hypertension and pleural effusion (two [1%] each).

280 group C, neutropenia (four [6%]) and pleural effusion (two [3%]).

281 g medium lobe atelectasis; bilateral pleural effusion was also present.

282 1 hemodynamically insignificant pericardial effusion was observed at follow-up.

283 In 44% of the patients, synovial effusion was presented.

284 ntified in either treatment arm, and pleural effusion was the only drug-related, nonhematologic adver

285 Pleural effusion was uncommon (2/64, 3%).

286 ecurrent, nonresponsive, and chronic OM with effusion) was greater than that on simple, acute OM in p

287 First occurrences of pleural effusion were reported with dasatinib, with the highest

288 Subpleural sparing and pleural effusion were seen approximately in one-fifth and one-si

289 Subpleural sparing and pleural effusion were seen in approximately 23% (28/120) and 17%

290 Pleural effusions were classified as exudates or transudates acc

291 own chylous (n = 17) and nonchylous (n = 12) effusions were evaluated with MRI.

292 The incidence of pleural effusions were not significantly different between both

293 ns.Methods: Patients presenting with pleural effusions were prospectively recruited to an observation

294 Thirty three (26%) of the 128 pleural effusions were transudates and 95 (74%) were exudates.

295 as hyperacusis and chronic otitis media with effusion, which is prevalent in young children with lang

296 nt a method for predicting protein function, Effusion, which uses a sequence similarity network to ad

297 hyperintense (infection), and a homogeneous effusion with the signal intensity of fluid (nonspecific

298 gnificantly higher rate of large pericardial effusions with LBN compared with MPN (8.1% versus 0.9%;

299 phy (CT) findings for characterizing pleural effusions with the use of attenuation values.

300 heart failure symptoms or recurrent pleural effusions within 2 years of lung transplantation.